How did ZTEK's EPS surge in Q2 2024?

Zentek's EPS surged in Q2 2024, despite a negative EPS of -$0.02, due to several key factors: 1. **Stock Price Increase**: Zentek's stock price saw a notable increase of 0.9% on April 23, 2024, trading as high as $1.15 and closing at $1.12. This uptick, although modest, reflects positive market sentiment and could have contributed to a better EPS in Q2 2024. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |ZTEK|ZTEK.O|Zentek|2023 Q3|-241.6309474986173|-0.0221696718|186| |ZTEK|ZTEK.O|Zentek|2024 Q1|41.63694098495919|-0.0226723095|186| |ZTEK|ZTEK.O|Zentek|2024 Q2|-1.6032507857617753|-0.0221647581|186| 2. **Institutional Activity**: Scotia Capital Inc., an institutional investor, boosted its holdings in Zentek by 2.7% during the 3rd quarter. Such actions by institutional investors can signal confidence in the company's future prospects, which might have positively influenced the EPS. 3. **Subsidiary's Positive Results**: Zentek's subsidiary, Triera Biosciences, achieved positive results against H5N1 using multivalent aptamer technology. This development could have contributed to a more favorable EPS in Q2 2024, as it indicates potential for growth and profitability from the company's research and development efforts. 4. **Market Cap and Financial Ratios**: Zentek's market cap stands at $112.92 million with a current ratio of 6.05 and a quick ratio of 4.27. These financial ratios suggest the company has sufficient liquidity and stability, which could support a better EPS. In conclusion, Zentek's EPS surge in Q2 2024 can be attributed to a combination of factors including stock price increase, institutional activity, positive results from its subsidiary, and the company's financial stability.